Home » Topics » Disease categories and therapies » Hematologic

Hematologic
RSS

Novel class of Factor XIIIa inhibitors synthesized by Apotex

March 1, 2005

Therapeutic benefits of rFVIIa in patients with acute intracerebral hemorrhage

Feb. 28, 2005

Novel factor Xa (FXa) inhibitors discovered at Merck KGaA

Feb. 18, 2005

Effects of FK-419, a GPIIb/IIIa antagonist, in a model of ischemic brain injury

Feb. 17, 2005

Thrombopoietin receptor (TPOR) activators disclosed by Nissan Chemical

Feb. 16, 2005

Update on the efficacy of rhThrombin in the management of surgery-associated bleeding

Feb. 15, 2005

New anticoagulant agents reported by Bristol-Myers Squibb

Feb. 14, 2005

Novel anticoagulant agents discovered at Lilly

Feb. 11, 2005

Arixtra receives new approval in Europe

Feb. 10, 2005

Portola begins phase Ib trial for oral anticoagulant

Feb. 9, 2005

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Aug. 3, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...